Other

Abbvie Inc.

Abbott Research B.v.

Andrea Best

Sandeep Dutta

Wei Liu

Jerry A Hall

John Powell

Duncan Casson

Mark Maginn

Rita I Jain

Earle Lockhart

Steven E Marx

James W Thomas

Pamela Giang Vo

The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.

Antibodies against nerve growth factor (NGF) with enhanced in vivo stability

The present invention generally provides a method of treatment and improvement of quality of life for patients adversely affected by various pain conditions. One preferred embodiment provides a method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back pain in a patient in need thereof, comprising providing at least one or two dosage form having about 15 mg of hydrocodone and its salt and about 500 mg of acetaminophen, once, twice or thrice daily. Preferably, the dosage form is about 30 mg of hydrocodone and about 1000 mg of acetaminophen taken twice daily. Alternatively, the dosage form is about 15 mg of hydrocodone and about 500 mg of acetaminophen taken twice daily.

Extended release hydrocodone acetaminophen and related methods and uses thereof

Growing community of inventors

Lake Forest, IL, United States of America

Andrea Best